{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002858","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.647963+00:00","generated_at":"2026-05-28T03:39:21.197170+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kiniksa reports 2024 ARCALYST net product revenue $416.4M (+79% YoY); guides 2025 to $560-580M","bullets":["ARCALYST net product revenue: Q4 2024 $121.9M, FY 2024 $416.4M (unaudited), ~79% YoY growth.","2025 ARCALYST net product revenue guidance: $560M to $580M.","Approximately 13% of target 14,000 multiple-recurrence pericarditis patients actively on ARCALYST as of Q4 2024.","Cash, cash equivalents, and short-term investments of $243.6M as of Dec 31, 2024; expects to remain cash flow positive annually.","Over 2,850 prescribers have written ARCALYST prescriptions; average therapy duration ~27 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002858","json":"https://secwatch.observer/filing/0001104659-25-002858.json","markdown":"https://secwatch.observer/filing/0001104659-25-002858.md","text":"https://secwatch.observer/filing/0001104659-25-002858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925002858/0001104659-25-002858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925002858/tm252986d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:39:21.197170+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}